Huidong Shi

20090264306, Oct 22, 2009

Oct 27, 2006

12/091718

Charles W. Caldwell - Columbia MO, US
Huidong Shi - Martinez GA, US
Farahnaz Rahmatpanah - Newport Beach CA, US
Kristen H. Taylor - Columbia MO, US
Douglas E. Laux - Iowa City IA, US
Deiter J. Duff - Columbia MO, US
Juyuan Guo - Columbia MO, US

Curators of the University of Missouri - Columbia MO

C40B 30/04
C12Q 1/68

506 9, 435 6

Differential Methylation Hybridization (DMH) was used to identify novel methylation markers and methylation profiles for hematopoieetic malignancies, leukemia, lymphomas, etc. (e.g., non-Hodgkin's lymphomas (NHL), small B-cell lymphomas (SBCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL), chronic lymphocytic leukemia (CLL), multiple myeloma (MM), acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), etc.). Particular aspects provide novel biomarkers for NHL and subtypes thereof (e.g., MCL, B-CLL/SLL, FL, DLBCL, etc.), AML, ALL and MM, and further provide non-invasive tests (e.g. blood tests) for lymphomas and leukemias. Additional aspects provide markers for diagnosis, prognosis, monitoring responses to therapies, relapse, etc., and further provide targets and methods for therapeutic demethylating treatments. Further aspects provide cancer staging markers, and expression assays and approaches comprising idealized methylation and/or patterns” (IMP and/or IEP) and fusion of gene rankings.

20100248228, Sep 30, 2010

Mar 27, 2009

12/383790

Michael Xia Wang - Columbia MO, US
Huidong Shi - Martinez GA, US
Srilatha Nalluri - Augusta GA, US

The Curators of the University of Missouri - Columbia MO

C12Q 1/68

435 6

The present invention provides a detecting method of detecting malignant cells in a patient's specimen or a biological sample. Specifically, the inventive method includes the steps of extracting a genomic DNA, digesting said genomic DNA with one or multiple methylation sensitive restriction enzymes, and amplifying by PCR with one or multiple selected primers. The PCR can be performed in a conventional or a real-time platform. The inventive method can detect leukemia cells in 90% ALL patients at a sensitivity of up to 10. The inventive method also provides broad clinical applications in cancer (including hematopoietic and solid tumors) screening and risk assessment, early detection and diagnosis confirmation, and therapeutic monitoring, minimal residual disease detection and prognostic prediction.

7563567, Jul 21, 2009

Apr 14, 2003

10/414540

Tim Hui-Ming Huang - Columbia MO, US
Huidong Shi - Columbia MO, US

The Curators of the Univeristy of Missouri of Columbia - Columbia MO

C12Q 1/68
C12P 19/34
C07H 21/04

435 6, 435 912, 536 2431, 536 2432, 536 2433

Novel methods are herein provided for high-throughput, dual analysis of DNA methylation and gene expression, and triple analysis of DNA methylation, gene expression and gene-associated histone acetylation in cancer cells using arrayed expressed CpG island sequence tags (ECISTs). ECISTs correspond to genomic DNA fragments comprising GC-rich segments along with promoter and/or exon (e. g. , first exon) portions of genes. The GC-rich segments are useful for screening hypermethylated CpG sites in cancer cells, while the corresponding promoter and exon-containing portions are useful for determining corresponding transcript levels and assessing histone acetylation. Also provided are high-throughput methods for either confirming methylation-dependent gene silencing, or identifying therapeutically effective demethylating agents, using the ECIST array panels to identify hypermethylated loci, and measure expression levels thereof after cellular exposure to demethylating agents. Further provided are high-throughput methods for distinguishing between direct (primary) demethylation-dependent gene up-regulation, and indirect (secondary) demethylation-dependent up-regulation within apparent epigenetic cascades.